FilingSEC EDGAR6-K
OKYO Pharma Announces First Patients Enrolled in Phase 3 Trial for Neuropathic Corneal Pain
· SEC accepted
StagePhase 3
Filing content
The company announced the enrollment of the first patients in the Phase 3 NEPTUNE trial for its lead candidate, urcosimod, to treat neuropathic corneal pain.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…